Treatment Endpoints in Acute Decompensated Heart Failure
急性失代偿性心力衰竭的治疗终点
基本信息
- 批准号:7916677
- 负责人:
- 金额:$ 16.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAdmission activityAdverse eventAftercareBehavioralBudgetsCaringClinicalClinical DataClinical InvestigatorClinical ResearchCohort StudiesComplementComplexConsumptionCoronaryCoronary ArteriosclerosisCoronary Artery BypassDataDecision MakingDecision ModelingDevelopmentDiagnosisDiseaseEconomic BurdenEmergency SituationEnrollmentEnvironmentEventFellowshipFunctional disorderFutureGoalsGuidelinesHealthHealth behaviorHealthcareHealthcare SystemsHeart failureHome environmentHospital MortalityHospitalizationHospitalsHourIncidenceIndividualInpatientsInterventionInterviewKnowledgeLaboratoriesLength of StayMeasuresMedicalMentorsMethodologyModelingMorbidity - disease rateNational Heart, Lung, and Blood InstituteNatriuretic PeptidesOutcomeOutcomes ResearchParentsPatient DischargePatientsPhysiciansPhysiologicalProcessQualifyingQuality of CareResearchResearch MethodologyResearch PersonnelResourcesRiskRisk BehaviorsRisk MarkerScienceStratificationTargeted ResearchTestingTherapeuticTimeUncertaintyWorkabstractingbaseclinical careclinical decision-makingcohortcostcost effectivenessevidence baseexperiencehigh riskimprovedinnovationinsightmathematical modelmortalitypatient populationpractical applicationprogramsprospectiverecidivismsocialsuccesstreatment response
项目摘要
DESCRIPTION (provided by applicant): A fundamental question faced by physicians treating acute decompensated heart failure (ADHF) is 'When has treatment worked sufficiently for safe discharge, and who requires further treatment?' Patients with ADHF have a high incidence of morbidity and mortality. Current guidelines for emergency department (ED) and hospital disposition of patients with ADHF are based on limited empirical evidence. This creates clinical uncertainty regarding disposition, leads to prolonged hospitalizations, higher costs and increased resource consumption. Conducting a project to answer this question, in combination with carefully planned didactics and mentoring from distinguished researchers, will allow me to develop as an independent clinical investigator with a primary focus on decision making in patients with ADHF. The ED is the portal of entry for the majority of ADHF admissions and presents fertile ground for prospectively studying decision making. My specific aims are: 1) to further develop knowledge in clinical research, advanced modeling, and decision sciences to advance my development as an independent clinical investigator and 2) to develop a prediction rule from readily available clinical data that helps physicians identify ADHF patients for whom early discharge from the ED and hospital is safe after treatment is initiated. In recognition of the importance of the ED in ADHF care, the NHLBI is supporting our observational cohort study of 1800 ED patients to develop a prediction rule for initial risk-stratification (STRATIFY- 1R01HL088459). To complete my aim, I will collect additional data on a subset of 500 patients from STRATIFY whose baseline data is collected within 1 hour of ED therapy. In addition to the baseline data from STRATIFY, the current proposal will collect clinical and laboratory data 2-4 hours, 12-24 hours and 96 hours after treatment is begun. We will also interview patients to measure social and behavioral variables. We will use this additional data to develop a second prediction rule to assist physicians in identifying patients safe for early ED and hospital discharge after therapy is begun. This project is an ideal vehicle for practical application of didactic knowledge gained, offers an intensive clinical research experience, and promises to generate extensive preliminary data to fully expand a long-term research program. My clinical research, didactic program and advanced biostatistical and modeling coursework will be supervised by a highly qualified, multi-disciplinary team of talented individuals, Building from my completed Outcomes Research fellowship and previous research experience, this proposal will allow me to mature as a clinical investigator, develop a prediction rule for decision making in ADHF, and engender evidence- based research in a disease process with tremendous healthcare system implications. (End of Abstract)
描述(由申请人提供):治疗急性失代偿性心力衰竭(ADHF)的医生面临的一个基本问题是“何时治疗足以安全出院,谁需要进一步治疗?”ADHF患者的发病率和死亡率很高。目前急诊科(艾德)和ADHF患者的医院处置指南是基于有限的经验证据。这造成了处置方面的临床不确定性,导致住院时间延长、成本增加和资源消耗增加。进行一个项目来回答这个问题,结合精心策划的教学和杰出研究人员的指导,将使我能够发展成为一名独立的临床研究者,主要关注ADHF患者的决策。艾德是大多数ADHF入院的入口,为前瞻性研究决策提供了肥沃的土壤。我的具体目标是:1)进一步发展临床研究、高级建模和决策科学方面的知识,以促进我作为独立临床研究者的发展; 2)根据现有临床数据制定预测规则,帮助医生识别ADHF患者,这些患者在开始治疗后尽早从艾德和医院出院是安全的。认识到艾德在ADHF治疗中的重要性,NHLBI支持我们对1800例艾德患者进行的观察性队列研究,以制定初始风险分层的预测规则(STRATIFY-1 R 01 HL 088459)。为了完成我的目标,我将从STRATIFY中收集500例患者的额外数据,这些患者的基线数据是在艾德治疗后1小时内收集的。除了来自STRATIFY的基线数据外,目前的提案将在治疗开始后2-4小时、12- 2 - 4小时和96小时收集临床和实验室数据。我们还将采访患者,以测量社会和行为变量。我们将使用这些额外的数据来开发第二个预测规则,以帮助医生识别早期艾德和治疗开始后出院的安全患者。该项目是实际应用所获得的教学知识的理想工具,提供了密集的临床研究经验,并有望产生广泛的初步数据,以充分扩大长期研究计划。我的临床研究,教学计划和先进的生物统计学和建模课程将由一个高素质的,多学科的人才团队监督,从我完成的成果研究奖学金和以前的研究经验,这个建议将使我成为一个成熟的临床研究者,制定一个预测规则,在ADHF决策,并在疾病过程中进行基于证据的研究,这对医疗保健系统有着巨大的影响。 (End摘要)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEAN PATRICK COLLINS其他文献
SEAN PATRICK COLLINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEAN PATRICK COLLINS', 18)}}的其他基金
Improving Diagnostic Accuracy for Acute Heart Failure
提高急性心力衰竭的诊断准确性
- 批准号:
10617357 - 财政年份:2021
- 资助金额:
$ 16.09万 - 项目类别:
Improving Diagnostic Accuracy for Acute Heart Failure
提高急性心力衰竭的诊断准确性
- 批准号:
10405617 - 财政年份:2021
- 资助金额:
$ 16.09万 - 项目类别:
Improving Diagnostic Accuracy for Acute Heart Failure
提高急性心力衰竭的诊断准确性
- 批准号:
10209800 - 财政年份:2021
- 资助金额:
$ 16.09万 - 项目类别:
A Randomized Trial of Protocolized Diuretic Therapy Compared to Standard Care in Emergency Department Patients with Acute Heart Failure
方案利尿疗法与标准护理在急诊室急性心力衰竭患者中的随机试验
- 批准号:
10507806 - 财政年份:2021
- 资助金额:
$ 16.09万 - 项目类别:
The Vanderbilt Emergency Medicine Research Training Program (VEMRT)
范德比尔特急诊医学研究培训计划 (VEMRT)
- 批准号:
8889712 - 财政年份:2011
- 资助金额:
$ 16.09万 - 项目类别:
The Vanderbilt Emergency Medicine Research Training Program (VEMRT)
范德比尔特急诊医学研究培训计划 (VEMRT)
- 批准号:
9289889 - 财政年份:2011
- 资助金额:
$ 16.09万 - 项目类别:
Treatment Endpoints in Acute Decompensated Heart Failure
急性失代偿性心力衰竭的治疗终点
- 批准号:
8345106 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
Treatment Endpoints in Acute Decompensated Heart Failure
急性失代偿性心力衰竭的治疗终点
- 批准号:
7679370 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
Treatment Endpoints in Acute Decompensated Heart Failure
急性失代偿性心力衰竭的治疗终点
- 批准号:
8262163 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
Treatment Endpoints in Acute Decompensated Heart Failure
急性失代偿性心力衰竭的治疗终点
- 批准号:
7531959 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Operating Grants